Aurinia Pharmaceuticals Stock Investor Sentiment

AUPH Stock  USD 9.12  0.14  1.56%   
Under 69 percent of all Aurinia Pharmaceuticals' traders are curious in acquiring. The analysis of the overall investor sentiment regarding Aurinia Pharmaceuticals suggests that a large number of traders are confidant. Aurinia Pharmaceuticals' investing sentiment shows overall attitude of investors towards Aurinia Pharmaceuticals.
  

Aurinia Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Aurinia Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at bizjournals.com         
Aurinia Pharmaceuticals laying off dozens in Montgomery County
bizjournals News
over a week ago at finance.yahoo.com         
Noema Pharma Appoints Volker Knappertz, M.D., as Executive Vice President of Research Development
Yahoo News
over a week ago at news.google.com         
Short Interest in Aurinia Pharmaceuticals Inc. Declines By 9.6 percent - MarketBeat
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Sunbelt Securities Inc. Cuts Stock Holdings in Aurinia Pharmaceuticals Inc.
news
over two weeks ago at investors.com         
Aurinia Pharmaceuticals Earns Relative Strength Rating Upgrade
Investors Business Daily at Macroaxis
over two weeks ago at simplywall.st         
Aurinia Pharmaceuticals Inc. Held Back By Insufficient Growth Even After Shares Climb 25
Simply Wall St News at Macroaxis
over two weeks ago at finance.yahoo.com         
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options
Yahoo News
over two weeks ago at zacks.com         
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options
zacks News
over two weeks ago at investing.com         
Kevin Tang buys 10.82 million in Aurinia Pharmaceuticals shares
Investing News at Macroaxis
over two weeks ago at investing.com         
Acquisition by Tang Kevin of 500000 shares of Aurinia Pharmaceuticals at 9.09 subject to Rule 16b-3
Investing News at Macroaxis
over two weeks ago at finance.yahoo.com         
While institutions own 40 percent of Aurinia Pharmaceuticals Inc. , retail investors are its largest...
Yahoo News
over two weeks ago at finance.yahoo.com         
Acquisition by Tang Kevin of 400000 shares of Aurinia Pharmaceuticals at 9.01 subject to Rule 16b-3
Yahoo News
over two weeks ago at www.macroaxis.com         
Acquisition by Tang Kevin of 300000 shares of Aurinia Pharmaceuticals at 8.91 subject to Rule 16b-3
Macroaxis News
over three weeks ago at simplywall.st         
We Might See A Profit From Aurinia Pharmaceuticals Inc. Soon
Simply Wall St News at Macroaxis
over three weeks ago at www.macroaxis.com         
Disposition of 25146 shares by Knappertz Volker of Aurinia Pharmaceuticals at 5.48 subject to Rule 1...
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Aurinia Pharmaceuticals that are available to investors today. That information is available publicly through Aurinia media outlets and privately through word of mouth or via Aurinia internal channels. However, regardless of the origin, that massive amount of Aurinia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aurinia Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aurinia Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aurinia Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aurinia Pharmaceuticals alpha.

Aurinia Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 4650 shares by Billen Daniel of Aurinia Pharmaceuticals at 11.26 subject to Rule 16b-3
10/21/2024
2
Disposition of 8733 shares by Jayne David R.w. of Aurinia Pharmaceuticals subject to Rule 16b-3
10/25/2024
3
Earnings call Aurinia Pharmaceuticals announced a 24 percent increase in total net revenue
11/07/2024
4
Disposition of 5241 shares by Smith Karen L. of Aurinia Pharmaceuticals at 8.43 subject to Rule 16b-3
11/11/2024
5
Aurinia Pharmaceuticals director Karen Smith sells 44,181 in stock
11/13/2024
6
Aurinia to Participate in Jefferies London Healthcare Conference
11/14/2024
7
Acquisition by Jayne David R.w. of 18641 shares of Aurinia Pharmaceuticals at 8.24 subject to Rule 16b-3
11/21/2024
8
Disposition of 25146 shares by Knappertz Volker of Aurinia Pharmaceuticals at 5.48 subject to Rule 16b-3
11/29/2024
9
Acquisition by Tang Kevin of 300000 shares of Aurinia Pharmaceuticals at 8.91 subject to Rule 16b-3
12/05/2024
10
Acquisition by Tang Kevin of 500000 shares of Aurinia Pharmaceuticals at 9.09 subject to Rule 16b-3
12/09/2024
11
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options
12/10/2024
12
Sunbelt Securities Inc. Cuts Stock Holdings in Aurinia Pharmaceuticals Inc.
12/12/2024
13
Aurinia Pharmaceuticals laying off dozens in Montgomery County
12/24/2024

Complementary Tools for Aurinia Stock analysis

When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets